Trexquant Investment LP purchased a new stake in Bath & Body Works, Inc. (NYSE:BBWI - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 80,612 shares of the company's stock, valued at approximately $3,125,000.
A number of other institutional investors have also made changes to their positions in BBWI. Golden State Wealth Management LLC bought a new stake in Bath & Body Works during the 4th quarter valued at approximately $26,000. SRS Capital Advisors Inc. lifted its holdings in shares of Bath & Body Works by 99.7% during the fourth quarter. SRS Capital Advisors Inc. now owns 659 shares of the company's stock worth $26,000 after buying an additional 329 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Bath & Body Works by 58.8% in the fourth quarter. UMB Bank n.a. now owns 905 shares of the company's stock valued at $35,000 after acquiring an additional 335 shares during the period. Lindbrook Capital LLC grew its stake in shares of Bath & Body Works by 81.9% in the fourth quarter. Lindbrook Capital LLC now owns 957 shares of the company's stock worth $37,000 after acquiring an additional 431 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in Bath & Body Works during the third quarter worth $39,000. 95.14% of the stock is currently owned by institutional investors.
Bath & Body Works Stock Down 3.9 %
NYSE:BBWI traded down $1.08 on Friday, reaching $26.54. The stock had a trading volume of 7,878,161 shares, compared to its average volume of 4,668,577. The company has a market capitalization of $5.69 billion, a P/E ratio of 6.47, a price-to-earnings-growth ratio of 0.92 and a beta of 1.69. Bath & Body Works, Inc. has a 1-year low of $24.96 and a 1-year high of $52.99. The stock has a fifty day moving average price of $32.99 and a 200-day moving average price of $33.98.
Bath & Body Works (NYSE:BBWI - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $2.09 EPS for the quarter, topping the consensus estimate of $2.04 by $0.05. Bath & Body Works had a negative return on equity of 44.03% and a net margin of 12.43%. The business had revenue of $2.79 billion for the quarter, compared to the consensus estimate of $2.78 billion. Sell-side analysts predict that Bath & Body Works, Inc. will post 3.3 earnings per share for the current fiscal year.
Bath & Body Works Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, February 21st were issued a $0.20 dividend. The ex-dividend date of this dividend was Friday, February 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 3.01%. Bath & Body Works's dividend payout ratio is 21.98%.
Bath & Body Works announced that its Board of Directors has approved a share repurchase program on Thursday, February 27th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are often an indication that the company's leadership believes its shares are undervalued.
Analyst Upgrades and Downgrades
Several research firms have issued reports on BBWI. JPMorgan Chase & Co. set a $47.00 price target on shares of Bath & Body Works in a research report on Thursday, February 27th. Telsey Advisory Group restated an "outperform" rating and set a $43.00 price target on shares of Bath & Body Works in a research note on Thursday, February 27th. Citigroup reduced their price objective on Bath & Body Works from $48.00 to $36.00 and set a "buy" rating for the company in a research report on Monday. Argus restated a "hold" rating on shares of Bath & Body Works in a research report on Friday, January 10th. Finally, Robert W. Baird raised their target price on Bath & Body Works from $45.00 to $47.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Four analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $44.06.
Check Out Our Latest Report on Bath & Body Works
Bath & Body Works Company Profile
(
Free Report)
Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.
See Also
Before you consider Bath & Body Works, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bath & Body Works wasn't on the list.
While Bath & Body Works currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
